Disc Medicine, Inc. IRON
Regular-session close
After hours · Nov 19, 4:26 PM ET
- YTD
- -4.16%
- 1 year
- -16.12%
5D -5.69 (-6.87%)
- Market cap
- 3.47B
- EPS (ttm)
- -6.34
- Shares out
- 45.54M
- Forward P/E
- -12.32
- YTD return
- -4.16%
- 1-year return
- -16.12%
- 50-day average
- 71.57
- 200-day average
- 70.92
- Enterprise value
- 2.93B
- Price / book
- 4.86
- Volume
- 646.41K
- Avg volume
- 943.68K
- Open
- 78.44
- Previous close
- 77.98
- Day's range
- 75.98 – 78.90
- 52-week range
- 40.00 – 99.50
- Beta
- 2.01
- Analysts
- Strong Buy
- Price target
- 127.69 (+67.8%)
- Earnings date
- Feb 25, 2027
Key statistics
- Free cash flow
- -112.66M
- Total cash
- 682.82M
- Total debt
- 61.09M
- Return on equity
- -41.29%
- Short % of float
- 17.13%
Fundamental scorecard
3 of 25 checks passed on IRON’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 104.00
- Target (mean)
- 127.69
- Target (high)
- 170.00
- Strong buy1
- Buy12
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -1.52.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -1.49 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.63 | -1.53 | +0.10 | +6.13% |
| Jul 30, 2026 | Jun 30, 2026 | -1.71 | -1.54 | +0.17 | +9.94% |
| May 5, 2026 | Mar 31, 2026 | -1.55 | -1.65 | -0.10 | -6.45% |
| Feb 26, 2026 | Dec 31, 2025 | -1.69 | -1.62 | +0.07 | +4.14% |
| Nov 6, 2025 | Sep 30, 2025 | -1.48 | -1.77 | -0.29 | -19.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Guggenheim | init | — | Buy |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 20, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 20, 2026 | Truist Securities | main | Buy | Buy |
| Oct 20, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 20, 2026 | Wedbush | main | Outperform | Outperform |
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- discmedicine.com
News
Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $170 Price Target
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $104
Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Disc Medicine, Inc. $IRON Holdings Raised by Alps Advisors Inc. Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127
Disc Medicine Q3 EPS $(1.53) Beats $(1.76) Estimate
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Disc Medicine to Participate in Upcoming Investor Conferences
Your note
Sign in to keep a note on IRON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AI DMI ,L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 21, 2025 | 0 |
| ASHIYA MONA | Director | Sale | Mar 23, 2025 | 0 |
| BITTERMAN KEVIN J | Director | Sale | Oct 20, 2026 | 0 |
| FRANCHI JEAN M | Chief Financial Officer | Sale | Apr 13, 2026 | 64,333 |
| KHARA RAHUL | Officer | Conversion of Exercise of derivative security | Aug 5, 2026 | 52,324 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Mar 23, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.55% | 4,803,145 | 365.57M | Sep 29, 2026 |
| Blackrock Inc. | 5.56% | 2,532,863 | 192.78M | Sep 29, 2026 |
| RA Capital Management, L.P. | 5.38% | 2,450,221 | 186.49M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 3.98% | 1,812,170 | 137.92M | Sep 29, 2026 |
| Wellington Management Group, LLP | 3.86% | 1,756,490 | 133.69M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 3.63% | 1,655,238 | 125.98M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 4.96% | 2,258,062 | 171.86M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.13% | 970,661 | 73.88M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.61% | 732,569 | 55.76M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.58% | 719,755 | 54.78M | Sep 29, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.42% | 647,794 | 49.30M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.24% | 566,760 | 43.14M | Jun 29, 2026 |
